Analyst Ratings For Nektar Therapeutics (NASDAQ:NKTR)
Today, Mizuho reiterated its Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a price target of $89.00.
Some recent analyst ratings include
- 2/14/2018-Mizuho Reiterated Rating of Buy.
- 1/10/2018-Canaccord Genuity Reiterated Rating of Buy.
- 11/13/2017-JPMorgan Chase & Co. Reiterated Rating of Positive .
- 11/7/2017-Cowen initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics (NASDAQ:NKTR) has insider ownership of 5.44% and institutional ownership of 96.00%.
- On 1/22/2018 Howard W Robin, CEO, sold 83,333 with an average share price of $75.82 per share and the total transaction amounting to $6,318,308.06.
- On 1/2/2018 Christopher A Kuebler, Director, sold 30,000 with an average share price of $58.66 per share and the total transaction amounting to $1,759,800.00.
- On 12/13/2017 Howard W Robin, CEO, sold 83,333 with an average share price of $55.69 per share and the total transaction amounting to $4,640,814.77.
- On 11/13/2017 John Nicholson, COO, sold 15,910 with an average share price of $37.78 per share and the total transaction amounting to $601,079.80.
- On 11/8/2017 Stephen K Doberstein, SVP, sold 396,323 with an average share price of $29.00 per share and the total transaction amounting to $11,493,367.00.
- On 11/6/2017 Maninder Hora, SVP, sold 5,117 with an average share price of $25.07 per share and the total transaction amounting to $128,283.19.
- On 11/1/2017 Howard W Robin, CEO, sold 83,334 with an average share price of $23.57 per share and the total transaction amounting to $1,964,182.38.
Recent Trading Activity for Nektar Therapeutics (NASDAQ:NKTR)
Shares of Nektar Therapeutics closed the previous trading session at 84.27 up +8.61 11.38% with 86.87129974365234 shares trading hands.